

hERG1a (D1Y2J) Rabbit mAb

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H R	Endogenous	135, 155	Rabbit IgG	#Q12809	3757

Product Usage Information**Application**

Western Blotting

Dilution

1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.

Specificity/Sensitivity

hERG1a (D1Y2J) Rabbit mAb recognizes endogenous levels of both mature and immature hERG1a protein. This antibody cross-reacts with proteins of unknown origin at 65 and 42 kDa in some cell lines. This antibody does not recognize hERG1b protein.

Species predicted to react based on 100% sequence homology

Monkey

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala223 of human hERG1a protein.

Background

hERG1(human ether-a-go-go-related gene potassium channel 1) is a voltage gated potassium channel alpha-subunit which mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr) (1,2). The hERG channel is composed of two subunits, 1a and 1b, which differ at amino terminus due to alternative splicing. Native hERG channels are heteromers of hERG1a with hERG1b. Both subunits contribute to IKr current (3-6).

Blockade of hERG currents induced by compounds or mutation of hERG encoding gene-KCNH2 causes ventricular arrhythmias associated with inherited and acquired long QT syndrome and cardiomyocyte apoptosis (7-10). Therefore, hERG channel is a primary target for the development of class III antiarrhythmic agents (11,12). The hERG channel is also inhibited by a variety of non-antiarrhythmic compounds, which result in side effects. Consequently, hERG channel blockage is a common counter screen when selecting therapeutic agents for various diseases (11,13,14).

Research studies have implicated hERG in cancer cell survival (15). In normal human adult tissue, hERG is expressed in heart, brain, myometrium, pancreas, and hematopoietic progenitors (16,17). hERG is expressed in various cancer cell lines of epithelial, neuronal, leukemic, and connective tissue origin but not in corresponding normal cells (18-22). Furthermore, hERG expression is associated with enhanced cancer cell proliferation, invasiveness, and poor prognosis (23,24).

Background References

1. Warmke, J.W. and Ganetzky, B. (1994) *Proc Natl Acad Sci U S A* 91, 3438-42.
2. Sanguinetti, M.C. and Tristani-Firouzi, M. (2006) *Nature* 440, 463-9.
3. Lees-Miller, J.P. et al. (1997) *Circ Res* 81, 719-26.
4. London, B. et al. (1997) *Circ Res* 81, 870-8.
5. Lees-Miller, J.P. et al. (2003) *Mol Cell Biol* 23, 1856-62.
6. Sale, H. et al. (2008) *Circ Res* 103, e81-95.
7. Curran, M.E. et al. (1995) *Cell* 80, 795-803.
8. Itoh, T. et al. (1998) *Hum Genet* 102, 435-9.
9. González-Juanatey, J.R. et al. (2003) *Circulation* 107, 127-31.
10. Gong, Q. et al. (2006) *J Biol Chem* 281, 4069-74.
11. Thomas, D. et al. (2006) *Curr Pharm Des* 12, 2271-83.
12. Staudacher, I. et al. (2010) *Curr Opin Drug Discov Devel* 13, 23-30.
13. Wible, B.A. et al. (2005) *J Pharmacol Toxicol Methods* 52, 136-45.
14. Yang, B.F. et al. (2004) *Acta Pharmacol Sin* 25, 554-60.
15. Jehle, J. et al. (2011) *Cell Death Dis* 2, e193.
16. Pond, A.L. et al. (2000) *J Biol Chem* 275, 5997-6006.
17. Rosati, B. et al. (2000) *FASEB J* 14, 2601-10.
18. Smith, G.A. et al. (2002) *J Biol Chem* 277, 18528-34.

19. Lastraoli, E. et al. (2004) *Cancer Res* 64, 606-11.
 20. Masi, A. et al. (2005) *Br J Cancer* 93, 781-92.
 21. Lin, H. et al. (2007) *J Cell Physiol* 212, 137-47.
 22. Gong, J.H. et al. (2010) *Oncol Rep* 23, 1747-56.
 23. Ding, X.W. et al. (2008) *J Surg Oncol* 97, 57-62.
 24. Shao, X.D. et al. (2008) *Cancer Biol Ther* 7, 45-50.
-

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human **R:** Rat

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.